Black Diamond Therapeutics Inc (BDTX) - Total Assets
Based on the latest financial reports, Black Diamond Therapeutics Inc (BDTX) holds total assets worth $125.03 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Black Diamond Therapeutics Inc - Total Assets Trend (2017–2025)
This chart illustrates how Black Diamond Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. Also see BDTX company net worth for the company's overall valuation and market capitalisation.
Black Diamond Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Black Diamond Therapeutics Inc's total assets of $125.03 Million consist of 92.6% current assets and 7.4% non-current assets. Review Black Diamond Therapeutics Inc (BDTX) total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 14.7% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2017–2025)
This chart illustrates how Black Diamond Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Black Diamond Therapeutics Inc stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Black Diamond Therapeutics Inc's current assets represent 92.6% of total assets in 2025, a decrease from 98.7% in 2017.
- Cash Position: Cash and equivalents constituted 14.7% of total assets in 2025, down from 98.2% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Black Diamond Therapeutics Inc Competitors by Total Assets
Key competitors of Black Diamond Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B
|
Denmark | Dkr9.17 Billion |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
|
USA | $890.92 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $183.97 Million |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
Black Diamond Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.28 | 8.73 | 9.16 |
| Quick Ratio | 7.28 | 8.73 | 9.16 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $99.55 Million | $129.92 Million | $215.19 Million |
Black Diamond Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Black Diamond Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.18 |
| Latest Market Cap to Assets Ratio | 0.77 |
| Asset Growth Rate (YoY) | 16.6% |
| Total Assets | $143.01 Million |
| Market Capitalization | $110.59 Million USD |
Valuation Analysis
Below Book Valuation: The market values Black Diamond Therapeutics Inc's assets below their book value (0.77x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Black Diamond Therapeutics Inc's assets grew by 16.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Black Diamond Therapeutics Inc (2017–2025)
The table below shows the annual total assets of Black Diamond Therapeutics Inc from 2017 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $143.01 Million | +16.61% |
| 2024-12-31 | $122.64 Million | -22.66% |
| 2023-12-31 | $158.57 Million | +1.48% |
| 2022-12-31 | $156.25 Million | -36.91% |
| 2021-12-31 | $247.68 Million | -24.87% |
| 2020-12-31 | $329.67 Million | +108.26% |
| 2019-12-31 | $158.29 Million | +205.44% |
| 2018-12-31 | $51.83 Million | +546.13% |
| 2017-12-31 | $8.02 Million | -- |
About Black Diamond Therapeutics Inc
Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutan… Read more